Invivyd, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · New Haven, CT
IVVD chart
What traders are saying about $IVVD
Latest postsInvivyd, Inc. news
- Pemgarda Pre-Exposure Prophylaxis Appears Safe, Effective in Blood Cancers, Advanced HIV
Clinical Oncology News ·
- Who Needs a Measles Antibody Most? Michael Mina, MD, PhD
The American Journal of Managed Care ·
- Invivyd (IVVD) Stock Price, Chart & Analysis
www.debelegger.nl ·
- Measles Antibody VMS063 and Immune Amnesia: Michael Mina, MD, PhD
The American Journal of Managed Care ·
- IVVD Q3'26 Earnings: EPS estimate is (0.13) USD
TradingView ·
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Yahoo Finance ·
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
Yahoo Finance ·
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
marketbeat.com ·
- Invivyd’s Covid-directed mAb hits Phase III safety goals
clinicaltrialsarena.com ·
- Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
investorshub.advfn.com ·
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Yahoo Finance ·
Invivyd, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | – |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M |
| Diluted EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 |
| Total assets (year end) | $276.9M | $129.5M | $229.2M | $383.2M |
| Cash and equivalents (year end) | $226.7M | $69.3M | $200.6M | $92.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Invivyd, Inc.
- Ticker
- IVVD (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New Haven, CT
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1832038
- Former names
- Adagio Therapeutics, Inc.
Frequently asked questions
What exchange is Invivyd, Inc. listed on?
Invivyd, Inc. trades on the Nasdaq under the ticker symbol IVVD.
What industry is Invivyd, Inc. in?
Invivyd, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Invivyd, Inc. headquartered?
Invivyd, Inc.'s business address on file with the SEC is in New Haven, CT.
When does Invivyd, Inc.'s fiscal year end?
Invivyd, Inc.'s fiscal year ends on December 31.
How much revenue did Invivyd, Inc. report?
Invivyd, Inc. reported $53.4M in revenue for calendar year 2025, according to its SEC filings.